本文選題：新輔助化療　切入點(diǎn)：宮頸癌　出處：《河北醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：卵巢癌、宮頸癌、子宮內(nèi)膜癌以及外陰癌是目前女性常見(jiàn)的四大惡性腫瘤,嚴(yán)重影響了女性患者的生命及生活質(zhì)量。為提升這些患者的生活質(zhì)量及生存率,新輔助化療是目前被婦科腫瘤專家研究的越來(lái)越多的一種治療惡性腫瘤的方法。新輔助化療是為惡性腫瘤患者達(dá)到理想腫瘤細(xì)胞減滅術(shù)及放療創(chuàng)造有利條件的一種治療方法。新輔助化療目前在卵巢癌中應(yīng)用的研究相對(duì)較多,且增加了晚期卵巢癌患者行滿意腫瘤細(xì)胞減滅手術(shù)的機(jī)會(huì);隨著目前宮頸癌患者的發(fā)病率趨于年輕化,而且某些年輕患者有強(qiáng)烈的生育要求,新輔助化療在宮頸癌中的應(yīng)用逐漸燃起婦科腫瘤專家及研究者的興趣;然而新輔助化療在子宮內(nèi)膜癌中應(yīng)用的研究相對(duì)較少,通過(guò)國(guó)內(nèi)外文獻(xiàn)得出目前也有婦科腫瘤專家將新輔助化療應(yīng)用于無(wú)法行滿意手術(shù)治療的子宮內(nèi)膜癌患者;為了減少晚期外陰癌患者術(shù)后的并發(fā)癥及增加患者術(shù)后的生存質(zhì)量,目前新輔助化療在外陰癌的應(yīng)用也不乏少數(shù)。本文基于國(guó)內(nèi)外對(duì)于新輔助化療在婦科惡性腫瘤(卵巢癌、宮頸癌、子宮內(nèi)膜癌以及外陰癌)的應(yīng)用現(xiàn)狀以及作用進(jìn)行了總結(jié);本文通過(guò)對(duì)應(yīng)用新輔助化療的患者術(shù)后的總生存期、無(wú)病生存期以及術(shù)后的生活質(zhì)量等的研究,對(duì)新輔助化療在四種惡性腫瘤中應(yīng)用的適應(yīng)癥、療效等方面進(jìn)行了總結(jié);最終對(duì)新輔助化療在惡性腫瘤中應(yīng)用的前景進(jìn)行了展望。
[Abstract]:Ovarian cancer, cervical cancer, endometrial carcinoma and vulvar cancer are the four most common malignant tumors in women at present, which seriously affect the life and quality of life of female patients. In order to improve the quality of life and survival rate of these patients, Neoadjuvant chemotherapy is one of the more and more methods for the treatment of malignant tumor, which has been studied by gynecological oncology experts. Neoadjuvant chemotherapy is a favorable condition for patients with malignant tumor to achieve ideal tumor cell reduction and radiotherapy. Neoadjuvant chemotherapy has been widely used in ovarian cancer. It also increases the chance of satisfactory tumor cell reduction in patients with advanced ovarian cancer. As the incidence of cervical cancer tends to be younger, and some young patients have strong fertility requirements, The application of neoadjuvant chemotherapy in cervical cancer has gradually aroused the interest of gynecologic oncology experts and researchers; however, there has been relatively little research on the application of neoadjuvant chemotherapy in endometrial carcinoma. According to the domestic and foreign literature, some gynecological oncology experts apply neoadjuvant chemotherapy to endometrial cancer patients who can not be treated satisfactorily, in order to reduce postoperative complications and increase the quality of life of patients with advanced vulvar cancer. At present, the application of neoadjuvant chemotherapy in vulvar cancer is also few. This paper summarizes the application and effect of neoadjuvant chemotherapy in gynecological malignant tumors (ovarian cancer, cervical cancer, endometrial carcinoma and vulvar cancer). In this paper, the total survival time, disease-free survival time and quality of life of patients with neoadjuvant chemotherapy were studied, and the indications and curative effects of neoadjuvant chemotherapy in four kinds of malignant tumors were summarized. Finally, the prospect of neoadjuvant chemotherapy in malignant tumors was prospected.
【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 劉嬋楨;張潔清;李力;;新輔助化療治療晚期子宮內(nèi)膜癌療效分析[J];中國(guó)實(shí)用婦科與產(chǎn)科雜志;2016年09期

2 狄文;殷霞;;新輔助化療在婦科惡性腫瘤中的應(yīng)用現(xiàn)狀和思考[J];中國(guó)實(shí)用婦科與產(chǎn)科雜志;2016年09期

3 袁航;張玉敏;黃文倩;陳婷婷;張師前;;美國(guó)婦科腫瘤學(xué)會(huì)和臨床腫瘤學(xué)會(huì)“2016初診晚期卵巢癌新輔助化療臨床實(shí)踐指南”解讀[J];中國(guó)實(shí)用婦科與產(chǎn)科雜志;2016年09期

，

本文編號(hào)：1631299